Page 2 - Breaking Science News Today

The meeting, cohosted by the World Heart Federation, will have a “distinct international flavor” beyond the late-breaking fare.

The trial missed its primary endpoint, but makes unique contributions; many see it as further evidence that the treatment helps iron-deficient patients with heart failure.

CHICAGO — Use of a point-of-care tool to support clinical decision-making in addition to rapid outpatient follow-up reduced the risk for death or CV hospitalizations for patients with acute HF presenting to the ED. “Implementation of this approach may lead to a pathway for early discharge from the hospital or emergency department and improved patient outcomes,” Douglas S. Lee,

CHICAGO — A novel CRISPR-based in vivo gene editing therapy reduced transthyretin levels in patients with hereditary transthyretin amyloidosis with cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a “progressive and fatal disease,” during which amyloid deposits cause impaired

Planners see the meetings Chicago return as a hybrid after 2 years relegated to cyberspace as a chance for first impressions on some just entering the field.

BOSTON — In patients with postinfarction ventricular septal defects, percutaneous and surgical treatments reduced mortality rates compared with historical medical therapy data, researchers reported at TCT 2022.The percutaneous and surgical strategies for postinfarction ventricular septal defects (VSD) did not differ significantly from each other in all-cause mortality at 5 years, but the

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the EVAPORATE (Effect of Vascepa on Improving Coronary ...